Protara Therapeutics, Inc. TARA · Stock Open Protara Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Protara Therapeutics, Inc. Analysis (TARA)
Is Protara Therapeutics, Inc. a good investment? Protara Therapeutics, Inc. (TARA) is currently trading at 2.33 USD. Market analysts have a consensus price target of 25.71 USD. This suggests a potential upside from current levels.
Earnings Schedule: Protara Therapeutics, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -1.69.
Investor FAQ
Does Protara Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Protara Therapeutics, Inc.?
Protara Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -1.36.
Company Profile
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 10, 2020 | 1:40 |
Community Discussion